Lipids News and Research

RSS

Lipids are a broad group of naturally-occurring molecules which includes fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K), monoglycerides, diglycerides, phospholipids, and others. The main biological functions of lipids include energy storage, as structural components of cell membranes, and as important signaling molecules.

New MALDI molecular imaging system offers spatial analysis of target metabolites

At the 58th ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announces a novel MALDI molecular imaging system based on the extreme performance of the solariX FTMS.

24 May 2010

NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for resected pancreatic cancer

NewLink Genetics Corporation today announced that preliminary data from its Phase 2 clinical trial evaluating the effect of HyperAcute®-Pancreas immunotherapy in patients with resected pancreatic cancer will be presented during a poster session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting held June 4-8, 2010 in Chicago, Illinois. A summary of the company's ASCO presentation is below.

20 May 2010

Pistachio nuts increase levels of antioxidants in blood of adults with high cholesterol: Researchers

Pistachio nuts, eaten as part of a healthy diet, can increase the levels of antioxidants in the blood of adults with high cholesterol, according to an international team of nutritional scientists.

20 May 2010

Regular consumption of pistachios lowers risk of CHD: Study

A new nut and blood lipid study published on May 10, 2010, in Archives of Internal Medicine, led by Dr. Joan Sabate and colleagues at Loma Linda University (Loma Linda, Calif.), confirms that eating nuts, like pistachios, have a total and LDL (bad)-cholesterol-lowering effect, supporting the evidence that regular nut consumption can lower the risk of coronary heart disease.

18 May 2010

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Cerenis Therapeutics, a biopharmaceutical company focused on discovering and developing novel HDL therapies, today announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute coronary syndromes. Results of the completed study provide evidence that the investigational therapy was safe and well-tolerated at all dose levels evaluated, including those intended for future clinical development.

18 May 2010

Mild-mannered organelles can detect virus invasion signals: Researchers

Within cells, an ancient antiviral duo can deliver a one-two knockout to thwart invading viruses, report researchers who have just unmasked the cellular sidekick that throws the first punch. The findings mean scientists must rethink the design of antiviral immunity and how the body fends off viruses of all types, including influenza and HIV.

14 May 2010

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

13 May 2010

Most breastfeeding mothers do not follow proper diet, study reveals

The study conducted at the University of Granada revealed that 94% of nursing mothers did not follow a proper diet, as they did not consume the recommended diary intake of fat, vitamins A, E and iron, and the intake of proteins was too high. The results obtained will serve to enhance breastfeeding mothers' diet and increase nutritional supply to the newborn.

12 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Oats is a highly nutritious cereal, which can be tolerated by large number of celiac patients. A range of commercial oat flours as well as specific oat flours produced from single varieties have been evaluated for their suitability for bread-baking. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of oat based foods.

5 May 2010

Animal study shows insulin prevents artery damage

Long suspected of worsening artery damage in patients with diabetes, insulin instead protects blood vessels, a new study by Joslin Diabetes Center scientists indicates.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.

4 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

DHA supplements during lactation increases DHA status in preterm infants

Docosahexaenoic acid (DHA), an omega-3 fatty acid, is essential for the growth and development of infants' brains. Very premature infants may be deficient in DHA because they miss out on the third trimester in utero when the fatty acid accumulates in tissues. In addition, their gastrointestinal system is immature, and health problems often increase the risk of malnutrition.

3 May 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Higher consumption of added sugars in processed foods associated with lower levels of HDL-C: Study

Consuming a higher amount of added sugars in processed or prepared foods is associated with lower levels of high-density lipoprotein cholesterol and higher levels of triglycerides, which are important risk factors for cardiovascular disease, according to a study in the April 21 issue of JAMA.

21 Apr 2010

Lipids News and Research

Further Reading

New MALDI molecular imaging system offers spatial analysis of target metabolites

NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for resected pancreatic cancer

Pistachio nuts increase levels of antioxidants in blood of adults with high cholesterol: Researchers

Regular consumption of pistachios lowers risk of CHD: Study

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Mild-mannered organelles can detect virus invasion signals: Researchers

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Most breastfeeding mothers do not follow proper diet, study reveals

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Genzyme to initiate $2 billion stock buyback

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Animal study shows insulin prevents artery damage

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

DHA supplements during lactation increases DHA status in preterm infants

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Higher consumption of added sugars in processed foods associated with lower levels of HDL-C: Study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News